- Trials with a EudraCT protocol (235)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
235 result(s) found for: glioblastoma.
Displaying page 5 of 12.
| EudraCT Number: 2022-003595-16 | Sponsor Protocol Number: GBM-MET | Start Date*: 2023-05-23 | |||||||||||
| Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA | |||||||||||||
| Full Title: Phase 2, open-label, single-arm study on the use of metformin as adjunctive therapy in high-grade glioma | |||||||||||||
| Medical condition: IDH-wildtype glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001659-37 | Sponsor Protocol Number: 26061 | Start Date*: 2007-06-25 | |||||||||||
| Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
| Full Title: Phase II Study of ZK 219477 in patients with recurrent glioblastoma | |||||||||||||
| Medical condition: Phase II study of ZK 219477 in patients with recurrent glioblastoma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001098-15 | Sponsor Protocol Number: CCRG14-001 | Start Date*: 2015-10-13 | ||||||||||||||||
| Sponsor Name:Antwerp University Hospital | ||||||||||||||||||
| Full Title: Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma | ||||||||||||||||||
| Medical condition: Newly diagnosed glioblastoma (WHO grade IV) in adults, treated with surgical resection and chemoradiation | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-001083-30 | Sponsor Protocol Number: VIGAS2 | Start Date*: 2019-06-02 |
| Sponsor Name:Karolinska Institutet | ||
| Full Title: A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients | ||
| Medical condition: Glioblastoma is an incurable brain tumor with very dismal prognosis. Substantial evidence demonstrates that cytomegalovirus (CMV) is present in 90-100% of malignant glioblastoma.We have observed th... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-003739-37 | Sponsor Protocol Number: CA209-498 | Start Date*: 2016-05-27 | |||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
| Full Title: A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA me... | |||||||||||||
| Medical condition: Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) AT (Completed) BE (Completed) DE (Completed) SE (Completed) ES (Ongoing) PL (Completed) DK (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-005838-19 | Sponsor Protocol Number: 2011.697 | Start Date*: 2012-12-28 | |||||||||||
| Sponsor Name:Hospics Civils de Lyon | |||||||||||||
| Full Title: MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF THE RESECTION OF GLIOBLASTOMAS - THE RESECT STUDY | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-011252-22 | Sponsor Protocol Number: CeTeG | Start Date*: 2010-07-09 | |||||||||||
| Sponsor Name:Medical Faculty, University of Bonn | |||||||||||||
| Full Title: Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG) | |||||||||||||
| Medical condition: Newly diagnosed patients with glioblastoma harbouring a methylated MGMT promoter | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004851-34 | Sponsor Protocol Number: BT008E | Start Date*: 2021-04-14 | |||||||||||
| Sponsor Name:INSIGHTEC | |||||||||||||
| Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004369-15 | Sponsor Protocol Number: 35RC16_9758_FLEGME | Start Date*: 2017-06-17 | |||||||||||
| Sponsor Name:Centre Hospitalier Universitaire de Rennes | |||||||||||||
| Full Title: FLEGME (FLuoresceine dans l’Exérèse des GlioMEs) : Intérêt de la fluorescéine dans la résection fluoroguidée des glioblastomes : une étude randomisée | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005177-29 | Sponsor Protocol Number: EORTC 26052-22053 | Start Date*: 2006-11-10 | |||||||||||
| Sponsor Name:EORTC | |||||||||||||
| Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma | |||||||||||||
| Medical condition: Patients with Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004705-59 | Sponsor Protocol Number: 406201215432 | Start Date*: 2013-12-17 |
| Sponsor Name:Hôpital Erasme, ULB | ||
| Full Title: Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed b... | ||
| Medical condition: Newly diagnosed glioblastoma (primary highly malignant brain cancer) patients Under treatment | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-006146-26 | Sponsor Protocol Number: BO21990 | Start Date*: 2009-05-11 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ... | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PT (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003755-15 | Sponsor Protocol Number: IRST191.05 | Start Date*: 2021-01-22 | |||||||||||
| Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
| Full Title: Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study | |||||||||||||
| Medical condition: glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-005644-24 | Sponsor Protocol Number: BERTES-01 | Start Date*: 2007-11-27 | |||||||||||||||||||||
| Sponsor Name:AMC-UvA | |||||||||||||||||||||||
| Full Title: Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients | |||||||||||||||||||||||
| Medical condition: Primary Glioblastoma Multiforme | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2013-003668-30 | Sponsor Protocol Number: KCP-330-004 | Start Date*: 2013-11-12 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutic, Inc. | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Recurrent glioblastoma or other brain cancer after failure of radiation therapy and temozolomide | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-010390-21 | Sponsor Protocol Number: ML21965 | Start Date*: 2010-02-10 | |||||||||||
| Sponsor Name:Roche Pharma AG | |||||||||||||
| Full Title: A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy... | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-000391-19 | Sponsor Protocol Number: CAT_AOSPTR001 | Start Date*: 2022-04-19 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA "S. MARIA" | |||||||||||||
| Full Title: A Single Arm Phase II Study of CAbozantinib in relapsing IDH-1wt, MET amplified Glioblastoma: (“CAT” Study) | |||||||||||||
| Medical condition: recurrent or progressive glioblastoma with c-MET hyperexpression | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
